OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain
OKYO Pharma Limited - American Depositary Shares (OKYO)
Company Research
Source: GlobeNewswire
Neuropathic corneal pain (NCP) is listed in the National Organization for Rare Disorders (NORD) as an orphan diseaseOKYO is the first company to have an IND application granted by the FDA for NCP The Phase 2 trial is designed as a randomized, placebo-controlled, double-masked study to treat 48 NCP patientsOK-101 demonstrated statistically significant pain relief in a recently completed Phase 2 trial of dry eye disease LONDON and NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a billion-dollar market, and for neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today that screening and recruitment of patients has started for a Phase 2 trial of OK-101 to treat NCP. The Phase 2 study is designed as a double-masked, randomized, 12-week placebo-contro
Show less
Read more
Impact Snapshot
Event Time:
OKYO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OKYO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OKYO alerts
High impacting OKYO Pharma Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
OKYO
News
- MUSQ Global Music Industry ETF and OKYO Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV [Yahoo! Finance]Yahoo! Finance
- MUSQ Global Music Industry ETF and OKYO Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVAccesswire
- OKYO Pharma to Present at International Tear Film and Ocular Surface Society ConferenceGlobeNewswire
- OKYO Pharma Limited (NASDAQ: OKYO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.MarketBeat
- OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal PainGlobeNewswire
OKYO
Sec Filings
- 10/30/24 - Form 6-K
- 10/23/24 - Form 6-K
- 10/16/24 - Form 6-K
- OKYO's page on the SEC website